From the end of 2023 to the beginning of this year, the drug resistance of mycoplasma infection is very serious, and how to effectively carry out drug resistance for these drug-resistant children is a concern of the pediatric community, the pharmaceutical community and the majority of parents. On January 28, the National Mycoplasma Pneumoniae Pneumonia Diagnosis and Treatment Response and Rational Drug Use Expert Exchange Meeting was held in Beijing, and 21 pediatric experts from all over the country conducted an in-depth study on the issue of children's medication.
The event was hosted by the journal "Exploration of Rational Use of Drugs in China". Zhao Yanyi, executive editor-in-chief of the journal "Exploration of Rational Use of Drugs in China", said that since the autumn and winter of 2023, the incidence of respiratory diseases in China has been high, especially the momentum of Mycoplasma pneumoniae infection, and there are many cases of Mycoplasma pneumoniae infection in children. According to the Guidelines for the Diagnosis and Treatment of Mycoplasma pneumoniae Pneumonia in Children (2023 Edition) issued by the National Health Commission, Mycoplasma pneumonia is the most common community-acquired pneumonia in children aged 5 years and above in China, with fever and cough as the main clinical manifestations. Clinically, macrolides have been indispensable antibacterial drugs in the fight against infection, especially their antibacterial effect on atypical pathogenic bacteria such as mycoplasma, which has been widely used and recognized in pediatric patients with mycoplasma susceptibility.
At the exchange meeting, Professor Lu Quan, head of the old respiratory group of the pediatric group of the Chinese Medical Association, member of the Antibiotic Professional Committee of the Expert Committee on Rational Drug Use of the National Health Commission, consultant of the expert group on children's medication, and former vice president of Shanghai Children's Hospital, Professor Wang Minggui, director of the Institute of Antimicrobial Research of Huashan Hospital and postdoctoral fellow of Harvard Medical School, Professor Xu Yingchun, director of the Laboratory Department of China and director of the Quality Management Center of the National Bacterial Resistance Monitoring Network of the Expert Committee on Rational Drug Use of the National Health Commission, delivered a special report.
Professor Lu Quan pointed out that the antibacterial drugs that can be taken orally at home can be used orally as much as possible, and excessive intravenous use of azithromycin is avoided, and the resistance rate of acetyl madeomycin is far lower than that of 14 and 15 cyclic drugs such as azithromycin, and acetylmedisycin is much more sensitive than erythromycin and azithromycin in vitro antibacterial activity of Mycoplasma pneumoniae.
According to Professor Wang Minggui, the results of the study showed that acetylmedisycin had a positive effect on all tested Mycoplasma pneumoniae (973% strain pair.
Ten. 4. 15-membered cyclomacrolide drug resistance), ureaplasma and mycoplasma hominis strains have good antimicrobial activity in vitro. For Mycoplasma pneumoniae and Mycoplasma hominis, the antimicrobial activity of acetylmaldimycin is much higher than that of other macrolide comparators; For ureaplasma strains, acetylmedisomycin has slightly higher antimicrobial activity than other macrolide comparators.
Professor Xu Yingchun pointed out that macrolides are the preferred drugs for Mycoplasma pneumoniae pneumonia (MPP), and 16-membered cyclic macrolide antimicrobial drugs have no inducible resistance and M-phenotypic resistance, suggesting that 16-membered cyclic macrolides such as acetyl medisomycin will have broader clinical application prospects.
After the keynote speech, Professor Zheng Bo, Director of the Institute of Clinical Pharmacology of Peking University, presided over the expert discussion, and the participating experts expressed many valuable views on the clinical application of drugs, the accumulation of real-world data, the response to drug resistance, and off-label use.
Professor Hu Xin of Beijing Hospital also expressed his opinions on the problem of drug resistance, the differential treatment of quinolones in different macrolides, and the pharmacokinetics and half-life of acetylmedisomycin.